There have been a few observational studies that have suggested there may be an increased risk of cancer while using glargine, a long acting insulin analogue.
There is a long term randomised controlled trial, Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, that should provide more evidence on this matter.
The current RGH e-Bulletin summarises the evidence from four observational studies.
Download the small file: Insulin glargine and associated cancer risk (245)
The 2009 RGH E-Bulletins are archived here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
cancer,
glargine,
insulin,
RGH E-bulletin
An inhaled insulin product (Exubera®) was marketed in the United States from September 2006 to October 2007. This was a powdered form of recombinant human insulin, delivered via an inhaler, and provided more rapid absorption of fast-acting insulin than subcutaneously injected insulin. This provided a closer match to the natural physiological release of insulin at mealtimes………………….
……………………data from several studies investigating a new form of inhaled insulin called technosphere insulin were released. This insulin has an onset of action that is evident within 10 minutes and peaks at 40 minutes, compared to 70 minutes with subcutaneous lispro insulin. This results in a profile closer to normal physiological glucose reduction.
Download the complete bulletin (pdf) here
The 2009 RGH E-Bulletins are archived by topic here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
Exubera,
inhaled,
insulin,
technosphere
There have been a few observational studies that have suggested there may be an increased risk of cancer while using glargine, a long acting insulin analogue. 
